Cytiva announces winner of Australia-NZ BioChallenge

Latest News

Cytiva has announced the winner of its first BioChallenge for the Australia and New Zealand region (ANZ).

The company said the competition attracted 32 proposals from academic institutions and start-up companies across the region’s biotechnology industry.

They were evaluated by a panel of independent judges.

VivaZome Therapeutics, an emerging exosome-derived therapies developer, was ultimately awarded the top prize valued at approximately $200,000.

VivaZome’s winning entry depicted the company’s efforts to develop a universal exosome manufacturing process with an aim is to produce off-the-shelf regenerative medicines.

According to Professor David Haylock, the CEO of VivaZome Therapeutics, “Our team is working to be a global leader in providing novel, valuable and safe exosome-derived therapies for devastating and life-threatening diseases. To make our vision real, we value the opportunity provided by BioChallenge to download industry experience and know-how from Cytiva.”

MTP Connect director Jarrod Belcher said, “The Cytiva Biochallenge provides funding and services & expertise to winning applicants to help grow local biomanufacturing in Australia. We appreciate industry support like this contributing to the commercialization efforts of Australia’s world-class research.”

Cytiva's Tim O’Meara, project leader for the ANZ BioChallenge, said, “Excellent research facilities, world-class capabilities and a strong but flexible regulatory regime have made ANZ a powerhouse of biotechnology. We hope BioChallenge can help discover and showcase promising industry researchers and companies with the support of Cytiva’s expertise, products, and services.”